Anti-scale composition for high severity processing of vinyl monomer streams

By using composition inhibitors that stabilize nitrogen oxygen radicals and phenylenediamine in ethylenically unsaturated monomers, the problem of premature polymerization of monomers at high temperatures is solved, and effective polymerization prevention under high harsh conditions is achieved , improves production efficiency and reduces economic losses.

CN118973995APending Publication Date: 2024-11-15ECOLAB USA INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380031721.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-01
Filing Date
2023-03-28
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Ethylene unsaturated monomers are prone to premature polymerization at high temperatures, resulting in equipment scaling and product contamination. The existing polymerization inhibitors fail at high temperatures and cannot effectively prevent polymerization.

Method used

The polymerization inhibitor is used to inhibit the polymerization of ethylenically unsaturated monomers by adding to the monomers, especially under high harsh conditions. .

Benefits of technology

It effectively prevents premature polymerization of ethylenically unsaturated monomers, reduces equipment scaling and product pollution, improves production efficiency, and reduces the frequency of operation shutdowns and economic losses.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118973995A_ABST
    Figure CN118973995A_ABST
Patent Text Reader

Abstract

An inhibitor composition for reducing undesirable polymerization during processing of a hydrocarbon stream loaded with a reactive vinyl monomer is provided. The polymerization inhibitor composition comprises at least a first inhibitor compound having a stable nitroxide radical and a second inhibitor comprising a phenylenediamine. Methods of inhibiting polymerization of monomers using the compositions of the present disclosure are also provided. The methods of inhibiting polymerization of monomers include the step of adding a composition of the present disclosure to the monomer. In some cases, the monomer is an ethylenically unsaturated monomer. Such ethylenically unsaturated monomers include, but are not limited to, vinyl acetate, acrylonitrile, acrylates, methacrylates, 1, 3-butadiene, styrene, isoprene, (meth) acrylic acid, and combinations thereof. Methods of preparing these polymerization inhibitors and compositions of the present disclosure are also provided.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present disclosure generally relates to compositions comprising a blend of polymerization inhibitors and methods of using the same. More specifically, the present disclosure relates to compositions comprising at least one compound having a stable nitroxide radical and a phenylenediamine that can be used to inhibit the polymerization of ethylenically unsaturated monomers. Background Art

[0002] The manufacture of ethylenically unsaturated monomers generally includes three stages: reaction, crude product recovery and product purification by fractionation. Distillation operations performed at high temperatures generally involve recovery and purification stages. Ethylenically unsaturated monomers (such as styrene, butadiene, isoprene, divinylbenzene, cyclopentadiene, dicyclopentadiene, vinyl acetate, acrylate and methacrylate monomers) are present in crude process streams or in refined products prepared by various chemical industrial processes. However, the monomers are highly reactive, particularly at high temperatures, in the presence of oxygen or when in contact with metal oxide surfaces. Therefore, these monomer types are very susceptible to undesirable polymerization by free radical polymerization. This problem is serious, particularly at high temperatures and in the presence of polymerization initiators (such as organic peroxides). The resulting polymer may be problematic and lead to equipment "fouling" and product contamination and consumption. Once the resulting polymer is precipitated from the solution during the processing stage and deposited on the equipment surface, production efficiency is reduced. As a result of fouling of process equipment, operations must be stopped to mechanically clean the equipment and / or remove undesirable polymers. Operational interruptions result in substantial economic losses for operators. The polymer may also remain in solution as a soluble product contaminant. Contamination may require additional processing steps to remove the contaminant polymer from the final product composition stream or stored product. All of the above problems necessitate the development and use of on-line chemical cleaning programs to mitigate fouling and thereby eliminate economically expensive operational downtime.

[0003] The premature polymerization of these monomers is usually alleviated by metering in a polymerization inhibitor that can eliminate or significantly reduce the premature polymerization of the monomers. Conventional polymerization inhibitors include stable free radicals that can effectively remove carbon-centered free radicals. Since operators now use raw materials that require high severity operating conditions, the use of conventional inhibitors has been proven to be ineffective. Conventional polymerization inhibitors (such as 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl (HTEMPO) and 4-oxo-2,2,6,6-tetramethylpiperidine-1-oxyl (OTEMPO)) usually degrade under high temperature processing environments and lose their effectiveness as polymerization inhibitors. Therefore, there is an urgent need to develop a novel polymerization inhibitor composition with high thermal stability and therefore not easily lose the inhibitory function under the process temperature of increase. Summary of the invention

[0004] A composition for inhibiting monomer polymerization is provided, which comprises a first inhibitor compound comprising a stable nitroxide free radical and a second inhibitor compound comprising phenylenediamine.

[0005] In some aspects, the first inhibitor compound has Formula (I):

[0006]

[0007] Where R 1 It is C 1 -C 22 Alkyl or aryl, wherein the alkyl and aryl groups are optionally substituted with one or more C 1 -C 22 Alkyl or aryl substituted.

[0008] In some aspects, the first inhibitor is selected from the group consisting of: 1-oxy-2,2,6,6-tetramethylpiperidin-4-ol; 4-methoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-ethoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-propoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-butoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-pentyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-hexyloxy-2,2,6,6-tetramethylpiperidin-1-ol 4-Heptyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-Octyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-Nonyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-Decyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-Undecyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-Dodecyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-Tridecyloxy-2,2,6,6-tetramethylpiperidin -1-oxy; 4-tetradecyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-pentadecyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-hexadecyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-heptadecyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-octadecyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-nonadecyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-decyloxy-2,2,6,6- tetramethylpiperidin-1-oxy; 4-eicosyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-heneicosyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-docosyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-(phenoxy)-2,2,6,6-tetramethylpiperidin-1-oxy; 4-(benzyloxy)-2,2,6,6-tetramethylpiperidin-1-oxy; 2,2,6,6-tetramethyl-4-(naphthalen-2-yloxy)piperidin-1-oxy; and any combination thereof.

[0009] In some aspects, the first inhibitor is a compound of Formula III:

[0010]

[0011] Where R 3 is -O· or -OH; and R 4 It is C 1 -C 22 Alkyl or aryl, wherein the alkyl and aryl groups are optionally substituted with one or more C 1 -C 22 Alkyl or aryl substituted.

[0012] In some aspects, the first inhibitor is selected from the group consisting of: 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl acetate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl propionate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl butyrate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl pentanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl hexanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl heptanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl octanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl nonanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl decanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl undecanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl dodecanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl 2-ethylhexanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl stearate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl dibenzoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl palmitate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl behenate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl 4-tert-butylbenzoate; and any combination thereof.

[0013] In some aspects, the second inhibitor compound is a phenylenediamine of Formula (IV) or Formula (V):

[0014]

[0015] Where X 1 and X 2 Independently C 1 -C 22 Alkyl or aryl, wherein the alkyl and aryl groups are optionally substituted with one or more C 1 -C 22 Alkyl or aryl substituted.

[0016] In some respects, X 1 and X 2 Independently C 1 -C 22 Alkyl or phenyl, wherein the alkyl and phenyl are optionally replaced by one or more C 1 -C 22 Alkyl or aryl substituted.

[0017] In some respects, X 1 and X 2 Independently C 1 -C10 Alkyl or phenyl, wherein the alkyl and phenyl are optionally replaced by one or more C 1 -C 22 Alkyl or aryl substituted.

[0018] In some respects, X 1 and X 2 Independently C 1 -C 5 Alkyl or phenyl, wherein the alkyl and phenyl are optionally replaced by one or more C 1 -C 22 Alkyl or aryl substituted.

[0019] In some aspects, the second inhibitor is selected from the group consisting of: 1,2-phenylenediamine, 1,4-phenylenediamine, N,N′-dimethyl-p-phenylenediamine, N,N′-di-sec-butyl-1,4-phenylenediamine, N,N′-di-1,4-dimethylpentyl-1,4-phenylenediamine, N,N′-diacetyl-1,4-phenylenediamine, N-tert-butyl-N′-phenyl-1,4-phenylenediamine, N,N′-diphenyl-1,4-phenylenediamine, and any combination thereof.

[0020] In some aspects, the first inhibitor compound is present in the composition at a concentration of about 0.01 wt % to about 80 wt %.

[0021] In some aspects, the second inhibitor compound is present in the composition at a concentration of about 0.01 wt % to about 50 wt %.

[0022] In some aspects, the molar ratio of the first inhibitor compound to the second inhibitor compound is from about 100:1 to about 1:100.

[0023] In some aspects, the composition further comprises an organic solvent.

[0024] In some aspects, the composition further comprises an ethylenically unsaturated monomer selected from the group consisting of vinyl acetate, acrylonitrile, acrylates, methacrylates, 1,3-butadiene, styrene, isoprene, acrylic acid, methacrylic acid, and any combination thereof.

[0025] A method of inhibiting polymerization of a monomer is provided. The method comprises adding any composition described herein to the monomer.

[0026] In some aspects, the monomers are provided in solution.

[0027] In some aspects, the solution further comprises one or more additional components selected from the group consisting of an acid, an organic solvent, and water.

[0028] In some aspects, the monomer is an ethylenically unsaturated monomer.

[0029] In some aspects, the composition is added to the monomer such that the concentration of the first inhibitor compound is from about 0.1 ppm to about 10,000 ppm.

[0030] In some aspects, the composition is added to the monomer such that the concentration of the second inhibitor compound is from about 0.1 ppm to about 10,000 ppm.

[0031] In some aspects, the monomer is selected from the group consisting of vinyl acetate, acrylonitrile, acrylates, methacrylates, 1,3-butadiene, styrene, divinylbenzene, isoprene, cyclopentadiene, dicyclopentadiene, acrylic acid, methacrylic acid, and any combination thereof.

[0032] The above has been a fairly extensive overview of the features and technical advantages of the present disclosure so that the following specific description may be better understood. Other features and advantages of the present disclosure will be described below, which constitute the subject matter of the claims of this application. It will be appreciated by those skilled in the art that the disclosed concepts and specific aspects may be readily used as a basis for modifying or designing other aspects for achieving the same purpose of the present disclosure. It will also be appreciated by those skilled in the art that such disclosure of equivalent aspects does not depart from the spirit and scope of the present disclosure as described in the appended claims. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] Specific embodiments of the present invention are described below in detail with reference to the accompanying drawings.

[0034] Figure 1 Shown are the comparative polymerization kinetics of untreated and treated styrene solutions under static test conditions at a high severity reaction temperature of 135°C.

[0035] Figure 2 The amount of polystyrene formed after 6 hours of polymerization at a high severity temperature of about 135°C is shown.

[0036] Figure 3 Comparative styrene polymerization kinetics under high severity conditions are shown. DETAILED DESCRIPTION

[0037] Various aspects of the present disclosure are described below. The relationship and function of various aspects of the elements can be better understood by reference to the following detailed description. However, various aspects are not limited to those explicitly described herein, and it should be understood that in some cases, details that are unnecessary for understanding various aspects disclosed herein, such as, for example, conventional synthesis and / or preparation, may have been omitted.

[0038] By increasing the process temperature above the typical range, the anti-fouling agents that had previously proven effective have been rendered ineffective. The new operating conditions are characterized as high severity. Before the temperature was raised to the high severity regime, the operation ran for more than 8 years without emergency shutdowns to remove fouling materials from the process equipment. Once the operating temperature was raised above the typical upper threshold, the fouling rate increased dramatically. It was often the case that the operation had to be stopped as a matter of emergency. This unplanned stoppage of operations is expensive. To prevent this from occurring, high temperature inhibitors had to be developed.

[0039] As used herein, "high severity" refers to conditions in a distillation process in which the heating medium has a temperature above a certain value. Depending on the heating medium, the temperature at which the "high severity" condition begins may be different. When the heating medium is water / condensate, a temperature of at least about 100°C may be considered to be "high severity". When the heating medium is low-pressure steam, a temperature of at least about 125°C may be considered to be "high severity". When the heating medium is medium-pressure steam, a temperature of at least about 160°C may be considered to be "high severity". When the heating medium is high-pressure steam, a temperature of at least about 180°C may be considered to be "high severity". When the heating medium is oil, a temperature of at least about 300°C may be considered to be "high severity".

[0040] The present disclosure relates to compositions of blends containing polymerization inhibitors and methods of using the same to inhibit polymerization of ethylenically unsaturated monomers. The polymerization inhibitor compositions of the present disclosure contain at least one compound having thermally and chemically stable nitroxide free radicals and phenylenediamine. The polymerization inhibitor composition can be a blend of multiple components, including components other than the above-mentioned compounds having stable nitroxide free radicals and phenylenediamine.

[0041] In the presence of polymerizable monomers, a "polymerization inhibitor" inhibits the polymerization of these monomers during the induction time under shutdown conditions. After the induction time has elapsed after the polymerization inhibitor is completely consumed, polymer formation occurs at the same rate as in the complete absence of the polymerization inhibitor.

[0042] Polymerization inhibitors and polymerization retarders are generally considered "anti-polymerization agents," which are compounds that can inhibit or reduce the formation of polymers from one or more free radically polymerizable compounds.

[0043] The term "fouling" refers to the formation of polymers, prepolymers, oligomers and / or other materials that are insoluble in the stream and / or precipitate out of the stream and deposit on the equipment under the operating conditions of the equipment. In turn, the inhibitor compositions of the present disclosure may be referred to as "antifouling" because they inhibit or reduce the formation of fouling polymers.

[0044] Compositions of the present disclosure

[0045] The present disclosure relates to a composition for inhibiting the polymerization of monomers, wherein the composition comprises a first inhibitor compound having a stable nitroxide free radical and a second inhibitor compound, phenylenediamine. In some aspects, the composition used herein is particularly useful under high severity conditions in a distillation column. In some aspects, the composition is used to inhibit the polymerization of monomers, wherein the monomer is an ethylenically unsaturated monomer. For example, the composition of the present disclosure can be used to inhibit the polymerization of ethylenically unsaturated monomers, and the ethylenically unsaturated monomers include, but are not limited to, vinyl acetate, acrylonitrile, acrylate, methacrylate, 1,3-butadiene, styrene, isoprene, acrylic acid, (meth) acrylic acid, and combinations thereof.

[0046] In some aspects, the compositions of the present disclosure can be used to inhibit the polymerization of ethylenically unsaturated monomers under high severity operating conditions.

[0047] In some aspects, the first inhibitor compound having a stable nitroxide radical is a compound of formula (I):

[0048]

[0049] Where R 1 It is H, C 1 -C 22 Alkyl, C 1 -C 22 Alkenyl, C 1 -C 22 Alkynyl, C 1 -C 22 Cycloalkyl, aryl, -C 1 -C 22 Alkylene aryl, -C(O)(C 1 -C 22 alkyl), -C(O)(C 1 -C 22 alkenyl), -C(O)(C 1 -C 22 Alkynyl), -C(O)(C 1 -C 22 Cycloalkyl), -C(O)(aryl) or -C(O)(C 1 -C 22 alkylene aryl), wherein the alkyl, cycloalkyl and aryl groups are optionally substituted by one or more C 1 -C 22 Alkyl, C 1 -C 22 Alkenyl, C 1 -C 22 Alkynyl or aryl substitution.

[0050] The term "aryl" refers to monocyclic, bicyclic (fused) and tricyclic (fused or spiro) hydrocarbon ring systems having a total of five to fourteen ring carbon atoms, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring carbon atoms. The term "aryl" can be used interchangeably with the term "aryl ring".

[0051] In some respects, R 1 Yes -C(O)(C 1 -C 22 alkyl), -C(O)(C 1 -C 22 alkenyl), -C(O)(C 1 -C 22 Alkynyl), -C(O)(C 1 -C 22 Cycloalkyl), -C(O)(aryl) or -C(O)(C 1 -C 22 alkylene aryl), wherein the alkyl, cycloalkyl and aryl groups are optionally substituted by one or more C 1 -C 22 Alkyl, C 1 -C 22 Alkenyl, C 1 -C 22 Alkynyl and aryl substitution.

[0052] In some aspects, R1 is C 1 -C 22 Alkyl or aryl, wherein the alkyl and aryl groups are optionally substituted with one or more C 1 -C 22 Alkyl or aryl substituted.

[0053] In some respects, R 1 is H. In some aspects, R 1 It is C 1 -C 22 In some aspects, R 1 It is C 1 -C 22 In some aspects, R 1 It is C 1 -C 22 In some aspects, R 1 It is C 1 -C 22 Cycloalkyl, wherein the cycloalkyl is optionally substituted with one or more C 1 -C 22 Alkyl, C 1 -C 22 Alkenyl, C 1 -C 22 In some aspects, R1 is an aryl group, wherein the aryl group is optionally substituted with one or more C 1 -C 22 Alkyl, C 1 -C 22 Alkenyl, C 1 -C 22 In some aspects, R 1 Yes-C 1 -C 22 Alkylene aryl, wherein the aryl group is optionally substituted with one or more C 1 -C 22 Alkyl, C 1 -C 22 Alkenyl, C 1 -C 22 In some aspects, R 1 Yes -C(O)(C 1 -C 22 In some aspects, R 1 Yes -C(O)(C 1 -C 12 In some aspects, R 1 Yes -C(O)(C 1 -C 6 In some aspects, R 1 is -C(O)(methyl). In some aspects, R 1 is -C(O)(ethyl). In some aspects, R 1 is -C(O)(propyl). In some aspects, R 1 is -C(O)(butyl). In some aspects, R 1 is a C(O)(C 1 -C 22 In some aspects, R 1 Yes -C(O)(C 1 -C 22 In some aspects, R 1 Yes -C(O)(C 1 -C 22 cycloalkyl), wherein the cycloalkyl is optionally substituted by one or more C 1 -C 22 Alkyl, C 1 -C 22 Alkenyl, C 1 -C 22 In some aspects, R 1 is -C(O)(aryl), wherein the aryl group is optionally substituted with one or more C 1 -C 22 Alkyl, C 1 -C22 Alkenyl, C 1 -C 22 In some aspects, R 1 Yes -C(O)(C 1 -C 22 alkylene aryl), wherein the aryl group is optionally substituted by one or more C 1 -C 22 Alkyl, C 1 -C 22 Alkenyl, C 1 -C 22 Alkynyl or aryl substitution.

[0054] Examples of compounds of formula (I) include, but are not limited to, 1-oxy-2,2,6,6-tetramethylpiperidin-4-ol; 4-methoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-ethoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-propoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-butoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-pentyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-hexyloxy-2,2,6,6-tetramethylpiperidin-1-ol -1-oxy; 4-heptyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-octyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-nonyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-decyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-undecyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-dodecyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-tridecyloxy-2,2,6,6-tetramethyl Piperidin-1-oxyl; 4-tetradecyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-pentadecyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-hexadecyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-heptadecyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-octadecyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-nonadecyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-decyloxy-2,2 , 6,6-tetramethylpiperidin-1-oxy; 4-eicosyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-heneicosyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-docosyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-(phenoxy)-2,2,6,6-tetramethylpiperidin-1-oxy; 4-(benzyloxy)-2,2,6,6-tetramethylpiperidin-1-oxy; or 2,2,6,6-tetramethyl-4-(naphthalen-2-yloxy)piperidin-1-oxy.

[0055] In other aspects, the first inhibitor compound has formula (II):

[0056]

[0057] Where R 2 Selected from H, C 1 -C 22 Alkyl, C 1 -C 22 Alkenyl, C 1 -C 22 Alkynyl, C 1 -C 22 Cycloalkyl, aryl, -C 1 -C 22 Alkylene, -C(O)(C 1 -C 22 alkyl), -C(O)(C 1 -C 22 alkenyl), -C(O)(C 1 -C 22 Alkynyl), -C(O)(C 1 -C 22 Cycloalkyl), -C(O)(aryl) and -C(O)(C 1 -C 22 alkylene), wherein the alkyl, alkylene, cycloalkyl and aryl groups are optionally substituted by one or more C 1 -C 22 Alkyl, C 1 -C 22 Alkenyl, C 1 -C 22 Alkynyl or aryl substitution.

[0058] In some respects, R 2 Yes -C(O)(C 1 -C 22 alkyl), -C(O)(C 1 -C 22 alkenyl), -C(O)(C 1 -C 22 Alkynyl), -C(O)(C 1 -C 22 Cycloalkyl), -C(O)(aryl) and -C(O)(C 1 -C 22 alkylene), wherein the alkyl, alkylene, cycloalkyl and aryl groups are optionally substituted with one or more C 1 -C 22 Alkyl, C 1 -C 22 Alkenyl, C 1 -C 22Alkynyl or aryl substitution.

[0059] In some respects, R 2 is H. In some aspects, R 2 It is C 1 -C 22 In some aspects, R 2 It is C 1 -C 22 In some aspects, R 2 It is C 1 -C 22 In some aspects, R 2 It is C 1 -C 22 Cycloalkyl, wherein the cycloalkyl is optionally substituted with one or more C 1 -C 22 Alkyl, C 1 -C 22 Alkenyl, C 1 -C 22 In some aspects, R 2 is an aryl group, wherein the aryl group is optionally substituted with one or more C 1 -C 22 Alkyl, C 1 -C 22 Alkenyl, C 1 -C 22 In some aspects, R 2 Yes-C 1 -C 22 Alkylene, wherein the alkylene is optionally substituted with aryl, the aryl is optionally substituted with one or more C 1 -C 22 Alkyl, C 1 -C 22 Alkenyl, C 1 -C 22 In some aspects, R 2 Yes -C(O)(C 1 -C 22 In some aspects, R 2 Yes -C(O)(C 1 -C 12 In some aspects, R 2 Yes -C(O)(C 1 -C 6 In some aspects, R 2 is -C(O)(methyl). In some aspects, R 2 is -C(O)(ethyl). In some aspects, R 2 is -C(O)(propyl). In some aspects, R 2is -C(O)(butyl). In some aspects, R 2 Yes -C(O)(C 1 -C 22 In some aspects, R 2 Yes -C(O)(C 1 -C 22 In some aspects, R 2 Yes -C(O)(C 1 -C 22 cycloalkyl), wherein the cycloalkyl is optionally substituted by one or more C 1 -C 22 Alkyl, C 1 -C 22 Alkenyl, C 1 -C 22 In some aspects, R 2 is -C(O)(aryl), wherein the aryl group is optionally substituted with one or more C 1 -C 22 Alkyl, C 1 -C 22 Alkenyl, C 1 -C 22 In some aspects, R 2 Yes -C(O)(C 1 -C 22 alkylene), wherein the alkylene is optionally substituted by an aryl group, the aryl group is optionally substituted by one or more C 1 -C 22 Alkyl, C 1 -C 22 Alkenyl, C 1 -C 22 Alkynyl or aryl substitution.

[0060] In some aspects, the compound of formula (II) is 2,2,6,6-tetramethylpiperidin-1,4-diol; 4-methoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-ethoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-propoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-butoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-pentyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-hexyloxy-2,2,6,6-tetramethylpiperidin-1 -ol; 4-heptyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-octyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-nonyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-decyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-undecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-dodecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-tridecyloxy-2,2,6,6-tetramethylpiperidin -1-ol; 4-tetradecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-pentadecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-hexadecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-heptadecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-octadecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-nonadecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-decyloxy-2,2,6 ,6-tetramethylpiperidin-1-ol; 4-eicosyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-heneicosyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-docosyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-(phenoxy)-2,2,6,6-tetramethylpiperidin-1-ol; 4-(benzyloxy)-2,2,6,6-tetramethylpiperidin-1-ol; or 2,2,6,6-tetramethyl-4-(naphthalen-2-yloxy)piperidin-1-ol.

[0061] In certain aspects, the compositions of the present disclosure comprise compounds of formula (I) and (II), respectively, wherein R 1 and R 2 For example, in some aspects, the compositions of the present disclosure comprise compounds of formula (I) and (II), respectively, wherein R 1 and R 2 are independently -C(O)(C 1 -C 22 In certain aspects, the compositions of the present disclosure comprise a first inhibitor compound and a second inhibitor compound of formula (I) and (II), respectively, wherein R 1 and R 2 are different.

[0062] The compounds of formula (II) with hydroxylamine disclosed in the present invention have advantages over the corresponding nitrogen oxides (compounds of formula (I)), such as the ability to provide additional polymerization inhibition, which will be explained more fully below. The general synthetic route of hydroxylamine to produce nitrogen oxides is to reduce its corresponding nitrogen oxide with a reducing agent as follows:

[0063]

[0064] Hydroxylamines of nitroxides have the potential to provide additional polymerization inhibition compared to the corresponding nitroxides in the presence of carbon-centered and oxygen-centered free radical initiators. This is explained as follows:

[0065]

[0066] Due to its weak NO-H bond in the compound, the hydroxylamine of nitrogen oxide is an excellent hydrogen donor, so it is an effective antioxidant. As an antioxidant, the hydroxylamine of nitroxide free radical easily reacts with oxygen-centered free radicals (such as peroxide free radicals), and it is converted into its corresponding nitroxide free radical. Nitrogen oxides are generally considered to be the most effective inhibitors because they have excellent inhibition ability by removing carbon-centered free radicals at a rate that almost controls diffusion. This rate is several orders of magnitude faster than phenolic compounds. However, their kinetic superiority is not always favorable. For example, when oxygen-centered free radicals exist as the main free radicals, it may lose its superiority. Another problem related to nitrogen oxides is its consumption by non-inhibition and undesirable reactions with process stream components or other inhibitor additives. Therefore, high nitrogen oxide inhibitor dosages are usually required for a given inhibition efficacy, making their use economically unattractive or even unfeasible.

[0067] In essence, when both oxygen-centered free radicals and carbon-centered free radicals are present, each hydroxylamine of the nitroxide is equivalent to a hydrogen donor plus a nitroxide anti-polymerizer, which is an attractive motivation provided by the hydroxylamine of the nitroxide. That is, one hydroxylamine of the nitroxide can eliminate one oxygen-centered free radical and one carbon-centered free radical, while the nitroxide can only eliminate the carbon-centered free radical.

[0068] In some aspects, the first inhibitor is a compound of Formula III:

[0069]

[0070] Where R 3 is -O· or -OH; and R 4 It is C 1 -C 22Alkyl or aryl, wherein the alkyl and aryl groups are optionally substituted with one or more C 1 -C 22 Alkyl or aryl substituted.

[0071] In some respects, R 3 In some aspects, R 3 It is -OH.

[0072] In some respects, R 4 is optionally replaced by one or more C 1 -C 22 Alkyl or aryl substituted C 1 -C 22 In some aspects, R 4 is optionally replaced by one or more C 1 -C 22 Alkyl or aryl substituted aryl.

[0073] Examples of compounds of formula (iii) include, but are not limited to, 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl acetate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl propionate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl butyrate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl pentanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl hexanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl heptanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl octanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl nonanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl decanoate; 6-tetramethylpiperidin-4-yl ester; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl undecanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl dodecanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl 2-ethylhexanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl stearate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl dibenzoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl palmitate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl behenate; or 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl 4-tert-butylbenzoate.

[0074] In some aspects, the second inhibitor compound is a phenylenediamine of Formula (IV) or Formula (V):

[0075]

[0076] Where X 1 and X 2 Independently C1 -C 22 Alkyl or aryl, wherein the alkyl and aryl groups are optionally substituted with one or more C 1 -C 22 Alkyl or aryl substituted.

[0077] In some aspects, the second inhibitor compound is a phenylenediamine of formula (IV). In some aspects, the second inhibitor compound is a phenylenediamine of formula (V).

[0078] Examples of phenylenediamines include, but are not limited to, 1,2-phenylenediamine, 1,4-phenylenediamine, N,N′-dimethyl-p-phenylenediamine, N,N′-di-sec-butyl-1,4-phenylenediamine, N,N′-di-1,4-dimethylpentyl-1,4-phenylenediamine, N,N′-diacetyl-1,4-phenylenediamine, N-tert-butyl-N′-phenyl-1,4-phenylenediamine, and N,N′-diphenyl-1,4-phenylenediamine.

[0079] In some aspects, the composition consists essentially of the first inhibitor compound and the second inhibitor compound. In other aspects, the composition consists of an organic solvent, a first inhibitor, and a second inhibitor.

[0080] In some aspects, the first inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 80% by weight. In some aspects, the first inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 70% by weight. In some aspects, the first inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 60% by weight. In some aspects, the first inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 50% by weight. In some aspects, the first inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 40% by weight. In some aspects, the first inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 30% by weight. In some aspects, the first inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 20% by weight. In some aspects, the first inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 10% by weight.

[0081] For example, in some aspects, the first inhibitor compound is present in the composition at a concentration of about 0.01 wt %, about 0.1 wt %, about 1 wt %, about 5 wt %, about 10 wt %, about 15 wt %, about 20 wt %, about 25 wt %, about 30 wt %, about 35 wt %, about 40 wt %, about 45 wt %, about 50 wt %, about 55 wt %, about 60 wt %, about 65 wt %, about 70 wt %, about 75 wt %, or about 80 wt %.

[0082] In some aspects, the second inhibitor compound is present in the composition at a concentration of about 0.01% to about 50% by weight. In some aspects, the second inhibitor compound is present in the composition at a concentration of about 0.01% to about 40% by weight. In some aspects, the second inhibitor compound is present in the composition at a concentration of about 0.01% to about 30% by weight. In some aspects, the second inhibitor compound is present in the composition at a concentration of about 0.01% to about 20% by weight. In some aspects, the second inhibitor compound is present in the composition at a concentration of about 0.01% to about 10% by weight.

[0083] For example, in some aspects, the second inhibitor compound is present in the composition at a concentration of about 0.01 wt %, about 0.1 wt %, about 1 wt %, about 5 wt %, about 10 wt %, about 15 wt %, about 20 wt %, about 25 wt %, about 30 wt %, about 35 wt %, about 40 wt %, about 45 wt %, or about 50 wt %.

[0084] In some aspects, the molar ratio of the first inhibitor compound to the second inhibitor compound is from about 100:1 to about 1:100. In some aspects, the molar ratio of the first inhibitor compound to the second inhibitor compound is from about 90:1 to about 1:90. In some aspects, the molar ratio of the first inhibitor compound to the second inhibitor compound is from about 80:1 to about 1:80. In some aspects, the molar ratio of the first inhibitor compound to the second inhibitor compound is from about 70:1 to about 1:70. In some aspects, the molar ratio of the first inhibitor compound to the second inhibitor compound is from about 60:1 to about 1:60. In some aspects, the molar ratio of the first inhibitor compound to the second inhibitor compound is from about 50:1 to about 1:50. In some aspects, the molar ratio of the first inhibitor compound to the second inhibitor compound is from about 40:1 to about 1:40. In some aspects, the molar ratio of the first inhibitor compound to the second inhibitor compound is from about 30:1 to about 1:30. In some aspects, the molar ratio of the first inhibitor compound to the second inhibitor compound is from about 20:1 to about 1:20. In some aspects, the molar ratio of the first inhibitor compound to the second inhibitor compound is from about 10:1 to about 1: 10. In some aspects, the molar ratio of the first inhibitor compound to the second inhibitor compound is about 1:1.

[0085] In some aspects, the composition further comprises one or more additional compounds selected from the group consisting of: 2,2,6,6-tetramethylpiperidin-1-oxyl; 2,2,6,6-tetramethylpiperidin-1-ol; 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-oxo-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-oxo- 2,2,6,6-tetramethylpiperidin-1-ol; 4-acetoxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-acetoxy-2,2,6,6-tetramethylpiperidin-1-ol 4-propionyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl 4-propionyloxy-2,2,6,6-tetramethylpiperidin-1-ol; and bis((2,2,6,6-tetramethylpiperidin-1-oxyl)-4-yl)oxalate. In some aspects, the composition further comprises 2,2,6,6-tetramethylpiperidin-1-oxyl. In some aspects, the composition further comprises 2,2,6,6-tetramethylpiperidin-1-ol. In some aspects, the composition further comprises 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl. In some aspects, the composition further comprises 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-ol. In some aspects, the composition also includes 4-oxo-2,2,6,6-tetramethylpiperidin-1-oxyl. In some aspects, the composition also includes 4-oxo-2,2,6,6-tetramethylpiperidin-1-ol. In some aspects, the composition also includes 4-acetoxy-2,2,6,6-tetramethylpiperidin-1-oxyl. In some aspects, the composition also includes 4-acetoxy-2,2,6,6-tetramethylpiperidin-1-ol. In some aspects, the composition also includes 4-acetoxy-2,2,6,6-tetramethylpiperidin-1-ol. In some aspects, the composition also includes 4-propionyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl. In some aspects, the composition also includes 4-propionyloxy-2,2,6,6-tetramethylpiperidin-1-ol. In some aspects, the composition also includes oxalic acid bis((2,2,6,6-tetramethylpiperidin-1-oxy)-4-yl) ester.

[0086] The composition can also optionally include one or more organic solvents. It will be appreciated by those of ordinary skill in the art that there are many organic solvents compatible with the composition of the present disclosure. For example, in some aspects, one or more organic solvents are selected from vinyl acetate, dimethyl phthalate, dimethyl formamide, toluene, xylene, high aromatic naphtha, acetonitrile, ethyl acetate, acetone, methylene chloride, tetrahydrofuran, hexane, dimethyl sulfoxide, N-methyl-2-pyrrolidone and combinations thereof. In some aspects, the composition also includes vinyl acetate. In some aspects, the composition also includes dimethyl phthalate. In some aspects, the composition also includes dimethyl formamide. In some aspects, the composition also includes toluene. In some aspects, the composition also includes xylene. In some aspects, the composition also includes high aromatic naphtha. In some aspects, the composition also includes acetonitrile.

[0087] In some aspects, the composition also includes one or more ethylenically unsaturated monomers. It will be appreciated by those of ordinary skill in the art that there are many ethylenically unsaturated monomers compatible with the composition of the present disclosure. For example, in some aspects, one or more ethylenically unsaturated monomers are selected from vinyl acetate, acrylonitrile, acrylate, methacrylate, 1,3-butadiene, styrene, isoprene, (meth) acrylic acid and combinations thereof. In some aspects, the composition also includes vinyl acetate. In some aspects, the composition also includes acrylonitrile. In some aspects, the composition also includes acrylate. In some aspects, the composition also includes methacrylate. In some aspects, the composition also includes 1,3-butadiene. In some aspects, the composition also includes styrene. In some aspects, the composition also includes isoprene. In some aspects, the composition also includes (meth) acrylic acid.

[0088] The compositions of the present disclosure are stable and are useful polymerization inhibitors even under acidic conditions. Therefore, the compositions of the present disclosure can be used to inhibit premature polymerization of monomers in manufacturing processes, particularly those carried out under acidic conditions. For example, the compositions of the present disclosure can be used to prevent the polymerization of acrylates, which can include but are not limited to acrylonitrile, acrylic acid, methacrylic acid and its esters, and vinyl acetate.

[0089] In some aspects, the compositions disclosed herein do not include 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl (HTEMPO). In some aspects, the compositions disclosed herein do not include 4-oxo-2,2,6,6-tetramethylpiperidin-1-oxyl (OTEMPO). In some aspects, HTEMPO and OTEMPO are not added to ethylenically unsaturated monomers.

[0090] Methods of using the compositions of the present disclosure

[0091] The present disclosure also relates to methods of inhibiting polymerization of monomers, comprising adding a composition of the present disclosure to the monomers. In some aspects, an effective amount of a composition of the present disclosure is added to the monomers, wherein an effective amount is any amount sufficient to inhibit polymerization of the monomers.

[0092] In some aspects, the monomer is an ethylenically unsaturated monomer. In some aspects, the monomer is an ethylenically unsaturated monomer selected from the following items: vinyl acetate, acrylonitrile, acrylate, methacrylate, 1,3-butadiene, styrene, 2-vinylbenzene, isoprene, cyclopentadiene, dicyclopentadiene, acrylic acid, (meth) acrylic acid and combinations thereof. In some aspects, the method disclosed herein can be used to inhibit the polymerization of vinyl acetate. In some aspects, the method disclosed herein can be used to inhibit the polymerization of acrylonitrile. In some aspects, the method disclosed herein can be used to inhibit the polymerization of acrylate. In some aspects, the method disclosed herein can be used to inhibit the polymerization of methacrylate. In some aspects, the method disclosed herein can be used to inhibit the polymerization of 1,3-butadiene. In some aspects, the method disclosed herein can be used to inhibit the polymerization of styrene. In some aspects, the method disclosed herein can be used to inhibit the polymerization of isoprene. In some aspects, the method disclosed herein can be used to inhibit the polymerization of acrylic acid. In some aspects, the method disclosed herein can be used to inhibit the polymerization of (meth) acrylic acid.

[0093] The composition of the present disclosure can be added to the fluid manually or automatically. The composition can also be added continuously and / or intermittently. Automatic addition can be accomplished by using a chemical dosing pump. The chemical dosing pump can be programmed to add a specific amount of the polymerization inhibitor composition or any component thereof to the fluid at certain time intervals. In optional aspects, the chemical dosing pump can be manually controlled to add a specific amount of the polymerization inhibitor composition or any component thereof to the fluid. Adding the currently disclosed polymerization inhibitor composition to the monomer will thus inhibit the polymerization of the monomer.

[0094] In some aspects, the monomer is provided as a pure liquid. In other aspects, the monomer is provided in a solution, hereinafter referred to as a "monomer solution".

[0095] In some aspects, the monomer solution also includes one or more additional components selected from acid, organic solvent, water and their combination. For example, in some aspects, the monomer solution includes one or more organic solvents selected from the following items: vinyl acetate, dimethyl phthalate, dimethylformamide, toluene, ethyl toluene, xylene, high aromatic naphtha, acetonitrile, ethyl acetate, acetone, methylene chloride, tetrahydrofuran, hexane, dimethyl sulfoxide, N-methyl-2-pyrrolidone and their combination. In some aspects, the monomer solution includes one or more acids selected from the following items: hydrochloric acid, hydrofluoric acid, hydrobromic acid, hydroiodic acid, nitric acid, phosphoric acid, sulfuric acid, boric acid, perchloric acid, formic acid, acetic acid, propionic acid, butyric acid, valeric acid, caproic acid, acetic acid, caprylic acid, undecanoic acid, lauric acid, oxalic acid, malonic acid, succinic acid, glutaric acid, adipic acid, pimelic acid and suberic acid. In some aspects, the monomer solution includes water.

[0096] In some aspects, the pH of the monomer solution is from about 1 to about 7. In some aspects, the pH of the monomer solution is from about 1 to about 6. In some aspects, the pH of the monomer solution is from about 2 to about 6. In some aspects, the pH of the monomer solution is from about 3 to about 6. In some aspects, the pH of the monomer solution is from about 4 to about 6. In some aspects, the pH of the monomer solution is from about 5 to about 6.

[0097] In some aspects, the composition is added to the monomer so that the concentration of the first inhibitor compound is from about 0.1 ppm to about 10,000 ppm. In some aspects, the composition is added to the monomer so that the concentration of the first inhibitor compound is from about 0.1 ppm to about 5,000 ppm. In some aspects, the composition is added to the monomer so that the concentration of the first inhibitor compound is from about 0.1 ppm to about 1,000 ppm. In some aspects, the composition is added to the monomer so that the concentration of the first inhibitor compound is from about 0.1 ppm to about 500 ppm.

[0098] In some aspects, the composition is added to the monomer so that the concentration of the second inhibitor compound is from about 0.1 ppm to about 10,000 ppm. In some aspects, the composition is added to the monomer so that the concentration of the second inhibitor compound is from about 0.1 ppm to about 5,000 ppm. In some aspects, the composition is added to the monomer so that the concentration of the second inhibitor compound is from about 0.1 ppm to about 1,000 ppm. In some aspects, the composition is added to the monomer so that the concentration of the second inhibitor compound is from about 0.1 ppm to about 500 ppm.

[0099] The methods of the present disclosure can be used to inhibit premature polymerization of monomers in manufacturing processes, particularly those conducted under acidic conditions. For example, the methods of the present disclosure can be used to prevent polymerization of acrylates, which can include but are not limited to acrylonitrile, acrylic acid, methacrylic acid and its esters, and vinyl acetate.

[0100] The methods of the present disclosure can also be used to prevent premature polymerization of styrene during the manufacturing and purification processes.

[0101] The method of the present disclosure can also be used in butadiene extraction processes. This utility stems from the equilibrium partition coefficient between the polar organic phase and the organic phase.

[0102] In some aspects, the compositions disclosed herein are used for distillation purification of olefins. For example, the composition can be added to a process stream before entering a distillation unit, or the composition can be added to a process stream in a distillation unit.

[0103] Method for preparing the polymerization inhibitor of the present disclosure

[0104] The present invention also relates to a process for preparing compounds of formula (III):

[0105]

[0106] in:

[0107] R 3 is -O· or -OH; and

[0108] R 4 It is C 1 -C 22 Alkyl, C 1 -C 22 Alkenyl, C 1 -C 22 Alkynyl, C 1 -C 22 Cycloalkyl, aryl and C 1 -C 22 Alkylaryl, wherein the cycloalkyl and aryl are optionally replaced by one or more C 1 -C 22 Alkyl, C 1 -C 22 Alkenyl, C 1 -C 22 Alkynyl or aryl substitution.

[0109] In some aspects, the method for preparing a compound of formula (III) comprises reacting a compound of formula (IIIa):

[0110]

[0111] Using compound (IIIb):

[0112]

[0113] Where R 5 It is C 1 -C 22 Alkyl or C 1 -C 22 alkenyl;

[0114] Workup in solution affords compounds of formula (III).

[0115] In some respects, R 3 In some aspects, R 3 It is -OH.

[0116] In some respects, R 4 It is C 1 -C 22 In some aspects, R 4 It is C 1 -C 12 In some aspects, R 4 It is C 1 -C6 alkyl. In some aspects, R 4 In some aspects, R 4 It's methyl.

[0117] In one aspect, R 3 Yes-O·and R 4 is methyl. On the other hand, R 3 Yes-O·and R 4 On the other hand, R 3 is -OH and R 4 is methyl. On the other hand, R 3 is -OH and R 4 It is ethyl.

[0118] In some respects, R 5 It is C 1 -C 22 In some aspects, R 5 It is C 1 -C 12 In some aspects, R 5 It is C 1 -C 6 alkyl.

[0119] In some respects, R 5 It is C 1 -C 22 In some aspects, R 5 It is C 1 -C 12In some aspects, R 5 It is C 1 -C 6 In some aspects, R 5 It is C 2 Alkenyl.

[0120] In some aspects, the method for preparing a compound of formula (III) comprises reacting a compound of formula (IIIa):

[0121]

[0122] Compounds using (IIIc):

[0123]

[0124] Workup in solution affords compounds of formula (III).

[0125] In some aspects, the compound of formula (IIIa) is treated with a compound of formula (IIIb) in the presence of a catalyst and heat. In some aspects, the compound of formula (IIIa) is treated with a compound of formula (IIIc) in the presence of a catalyst and heat. It will be appreciated by those of ordinary skill that there are many suitable catalysts that can be used to form a compound of formula (III) by treating a compound of formula (IIIa) with a compound of formula (IIIb) or (IIIc). For example, in some aspects, the catalyst is an amine-containing compound. In some aspects, the catalyst is 4-dimethylaminopyridine, also referred to as DMAP. In some aspects, a solution of a compound of formula (IIIa) and (IIIb) or (IIIc) is heated to a temperature of about 50°C to about 100°C. In some aspects, the solution is heated to a temperature of about 50°C to about 85°C.

[0126] In some aspects, the method for preparing a compound of formula (III) also includes purging the solution with a nitrogen stream. In some aspects, the step of purging the solution with a nitrogen stream is carried out simultaneously with the step of treating the compound of formula (IIIa) with a compound of formula (IIIb) to provide a compound of formula (III). In some aspects, the step of purging the solution with a nitrogen stream is carried out simultaneously with the step of treating the compound of formula (IIIa) with a compound of formula (IIIc) to provide a compound of formula (III). In some aspects, the step of purging the solution with a nitrogen stream is carried out after the step of treating the compound of formula (IIIa) with a compound of formula (IIIb) to provide a compound of formula (III). In some aspects, the step of purging the solution with a nitrogen stream is carried out after the step of treating the compound of formula (IIIa) with a compound of formula (IIIc) to provide a compound of formula (III). Without being bound by theory, the step of purging the solution with a nitrogen stream can be used to remove certain reaction byproducts, which push the reaction equilibrium to the formation of a compound of formula (III).

[0127] Example

[0128] Example 1: High severity static performance blank

[0129] Commercial styrene is transported and stored after being treated with 4-tert-butylcatechol (TBC) to prevent glue formation. Therefore, before commercial styrene is used in performance tests, TBC is removed by eluting through an alumina column to obtain fresh styrene. Styrene is diluted with toluene to a solution containing about 70% (w / w) styrene and about 30% (w / w) toluene. In 24 pressure-resistant glass tubes, about 10mL of styrene solution is added to each tube. After removing dissolved oxygen in the solution by bubbling nitrogen through the solution for about 2 minutes, the test tube is covered with a PTFE screw cap with a fluoroelastomer (FETFE) O-ring. All tubes are placed in a heating block preheated to about 135°C. After the first 15 minutes have passed, four reactor tubes are taken out from the heating block and then taken out at intervals of 15 minutes, with a total reaction time of about 90 minutes. In order to quench the polymerization, the four tubes are immediately placed in an ice bath and the reaction mixture is immediately diluted with toluene. The concentration of soluble polymer products in the reaction mixture is determined using a proprietary method.

[0130] Example 2: High severity static performance 25 ppm HTEMPO

[0131] A freshly prepared solution of commercial styrene and toluene was treated with 25 ppm of HTEMPO. The reaction kinetics of this solution was carried out as described in Example 1.

[0132] Example 3: High severity static performance 25 ppm 4-acetoxy TEMPO

[0133] A dosage of 25 ppm of 4-acetoxyTEMPO was added to a toluene-diluted styrene solution prepared according to the procedure in Example 2. Likewise, performance tests and polymer analysis were performed as in Example 1.

[0134] Example 4: High severity static performance 12.5 ppm HTEMPO and 12.5 ppm PDA

[0135] Anti-aggregation agent performance testing was performed as outlined in the above examples after treating the toluene-styrene solution with 12.5 ppm of HTEMPO and 12.5 ppm of the PDA prototype N,N'-di-sec-butylphenylenediamine.

[0136] Example 5: High severity static performance 12.5 ppm 4-acetoxy TEMPO and 12.5 ppm PDA

[0137] 12.5 ppm of 4-acetoxyTEMPO and 12.5 ppm of prototype PDA were metered into the reaction solution mixture of styrene and toluene as in Example 4. The kinetic studies were carried out very similarly to the preceding examples.

[0138] The results of the comparative study are shown in Figure 1 From this test, it is very clear that normally effective free radical polymerization inhibitors are less effective at temperatures above industrial operating conditions. When the polymerization is carried out at 135°C, HTEMPO has a short induction time. Similarly, Figure 1 As shown in the kinetic trends in Figure 2, 4-acetoxyTEMPO exhibits relatively low efficiency as an inhibitor.

[0139] The combined use of 12.5 ppm of HTEMPO and 12.5 ppm of PDA antipolymerizers did not result in better antipolymerizer performance than HTEMPO. In contrast, metering 12.5 ppm of 4-acetoxyTEMPO and 12.5 ppm of PDA into the reaction solution resulted in a very significant improvement in preventing polymerization at an abnormally high temperature of 135°C.

[0140] Example 6: CSTR performance test using existing products

[0141] During processing and purification of the reactive monomers, the process stream is continuously fed into the process column and likewise, the same stream is transferred out of the process equipment. Thus, the operation is carried out under the continuous flow of the process stream. In order to simulate the in-line process in the reboiler section or bottom of the column of the process column, a continuous stirred tank reactor (CSTR) is used instead of the capped tube in the above examples.

[0142] As previously described in Example 1, commercial styrene is freshly prepared by removing tert-butylcatechol using an alumina column. Instead of using pure styrene, it must be diluted with a suitable solvent having a boiling point higher than 150°C. Because it boils at about 162°C, p-ethyltoluene (pET) is used as a diluent. The dilution of styrene is to slow down the polymerization rate at 135°C, which is a high severity temperature in the program. A portion of the styrene (weighing 1400 grams) is diluted with p-ethyltoluene. 600 grams of p-ethyltoluene are added to 1400 grams of freshly prepared styrene to produce an untreated hydrocarbon stream. The solution therefore contains about 70% (w / w) styrene and about 30% (w / w) p-ethyltoluene. About 0.0100 grams of N, N, N'-di-sec-butylphenylenediamine is added to the solution, followed by about 0.0100 grams of 2,6-di-tert-butylphenol. This constitutes a reaction solution treated with about 100ppm of an existing anti-polymerization agent.

[0143] Approximately 65 mL of the treated solution was added to a continuous stirred tank reactor (CSTR). The CSTR was equipped with an inlet delivery line through which a pump added the reaction mixture to the reactor. An outlet delivery line was also connected to the outlet port of the CSTR. A second pump was connected to this line, which carried the effluent stream from the reactor. Both pumps were adjusted to produce a CSTR residence time of approximately 15 minutes. The reactor was placed on a heat-jacketed heating block, and the reaction temperature was set at 135°C using a thermocouple probe inserted directly into the reaction mixture. Due to the high boiling point imparted to the reaction solution by the addition of p-ethyltoluene, no evaporation or loss of the reaction solution was observed. Nevertheless, a reflux device was connected to the reactor to prevent loss of the reaction solution due to evaporation. As soon as the reaction temperature reached approximately 135°C, a sample of the effluent stream was collected. From then on, samples were collected at intervals of approximately 30 minutes. The polymer content in the effluent stream was analyzed using a proprietary method. After a total CSTR reaction time of approximately 6 hours, the average concentration of polystyrene was approximately 9019 ppm (see Figure 2 ).

[0144] Example 7: CSTR Performance Testing Using New High Severity Products

[0145] The performance of a 100 ppm high severity product prototype was prepared and tested using the same procedure used in Example 6. The product contained about 50% (w / w) 4-acetoxy TEMPO and about 50% (w / w) N,N'-di-sec-butylphenylenediamine. The polystyrene concentration after about 6 hours was about 7 ppm. This is within the background polymer content of styrene at ambient conditions.

[0146] The bar graph of the results is shown in Figure 2 and the polymerization kinetics trend is shown in Figure 3 From these results, it can be clearly seen that the prototype of the new antifouling agent composition exhibits significantly better anti-polymerization agent efficacy than the existing (50% (w / w) PDA and 50% (w / w) hindered phenol). The high severity anti-polymerization agent effectively inhibits polymerization at high severity temperatures.

[0147] All compositions and methods disclosed and claimed herein can be prepared and performed according to the present disclosure without undue experimentation. Although the present invention can be embodied in many different forms, specific preferred embodiments of the present invention are described in detail herein. The present disclosure is an illustration of the principles of the present invention and is not intended to limit the present invention to the specific embodiments shown. In addition, unless explicitly stated to the contrary, the use of the term "one / kind" is intended to include "at least one / at least one" or "one or more / one or more". For example, "compound" is intended to include "at least one compound" or "one or more compounds".

[0148] Any range given in absolute terms or in approximate terms is intended to cover both, and any definition used herein is intended to be clarifying and not restrictive. Although the numerical ranges and parameters describing the broad scope of the present invention are approximate, the numerical values ​​described in the specific embodiments are reported as accurately as possible. However, any numerical value inherently contains certain errors caused by the standard deviation found in its corresponding experimental measurement. In addition, all ranges disclosed herein are understood to cover any and all subranges (including all fractional values ​​and overall values) contained therein.

[0149] Any composition disclosed herein may comprise, consist of, or consist essentially of any element, component, and / or ingredient disclosed herein, or any combination of two or more of the elements, components, or ingredients disclosed herein.

[0150] Any method disclosed herein may comprise, consist of, or consist essentially of any method step disclosed herein or any combination of two or more of the method steps disclosed herein.

[0151] The transitional phrase "comprising," which is synonymous with "including," "containing," or "characterized by," is inclusive or open-ended and does not exclude additional unrecited elements, components, ingredients, and / or method steps.

[0152] The transitional phrase "consisting of" excludes any element, component, ingredient and / or method step not specified in the claim.

[0153] The transition phrase "consisting essentially of" limits the scope of a claim to the specified elements, components, ingredients and / or steps, and those that do not materially affect the basic and novel characteristics of the claimed invention.

[0154] As used herein, the term "about" means that the recited value is within the standard deviation found in their respective testing measurements, and if those errors are not determinable, "about" may mean, for example, within 5% of the recited value.

[0155] In addition, the present invention encompasses any and all possible combinations of some or all of the various aspects described herein. It should also be understood that the various changes and modifications made to the current preferred aspects described herein are obvious to those skilled in the art. Such changes and modifications may be made without departing from the spirit and scope of the present invention and without reducing its expected advantages. Therefore, the appended claims are intended to cover such changes and modifications.

Claims

1. A composition for inhibiting monomer polymerization, the composition comprising: a first inhibitor compound comprising a stable nitroxide radical; and A second inhibitor compound, said second inhibitor compound comprising a phenylenediamine.

2. The composition of claim 1, wherein the first inhibitor compound has formula (I): Where R1 is C1-C 22 Alkyl or aryl, wherein the alkyl and aryl groups are optionally substituted by one or more C1-C 22 Alkyl or aryl substituted.

3. The composition of claim 1, wherein the first inhibitor is selected from the group consisting of: 1-oxy-2,2,6,6-tetramethylpiperidin-4-ol; 4-methoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-ethoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-propoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-butoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-pentyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-hexyloxy-2 ,2,6,6-tetramethylpiperidin-1-oxyl; 4-heptyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-octyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-nonyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-decyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-undecyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-dodecyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-tridecyloxy-2,2,6, 6-Tetramethylpiperidin-1-oxyl; 4-tetradecyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-pentadecyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-hexadecyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-heptadecyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-octadecyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-nonadecyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-decyloxy-2,2,6 ,6-tetramethylpiperidin-1-oxyl; 4-eicosyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-heicosyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-docosyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-(phenoxy)-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-(benzyloxy)-2,2,6,6-tetramethylpiperidin-1-oxyl; 2,2,6,6-tetramethyl-4-(naphthalen-2-yloxy)piperidin-1-oxyl; and any combination thereof.

4. The composition of claim 1, wherein the first inhibitor is a compound of formula III: wherein R3 is -O· or -OH; and R4 is C1-C 22 Alkyl or aryl, wherein the alkyl and aryl groups are optionally substituted by one or more C1-C 22 Alkyl or aryl substituted.

5. The composition of claim 4, wherein the first inhibitor is selected from the group consisting of: 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl acetate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl propionate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl butyrate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl pentanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl hexanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl heptanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl octanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl nonanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl decanoate; 2,6,6-tetramethylpiperidin-4-yl ester; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl undecanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl dodecanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl 2-ethylhexanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl stearate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl dibenzoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl palmitate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl behenate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl 4-tert-butylbenzoate; and any combination thereof.

6. The composition according to any one of claims 1 to 5, wherein the second inhibitor compound is a phenylenediamine of formula (IV) or formula (V): Where X1 and X2 are independently C1-C 22 Alkyl or aryl, wherein the alkyl and aryl groups are optionally substituted by one or more C1-C 22 Alkyl or aryl substituted.

7. The composition of any one of claims 1 to 6, wherein the second inhibitor is selected from the group consisting of 1,2-phenylenediamine, 1,4-phenylenediamine, N,N′-dimethyl-p-phenylenediamine, N,N′-di-sec-butyl-1,4-phenylenediamine, N,N′-di-1,4-dimethylpentyl-1,4-phenylenediamine, N,N′-diacetyl-1,4-phenylenediamine, N-tert-butyl-N′-phenyl-1,4-phenylenediamine, N,N′-diphenyl-1,4-phenylenediamine, and any combination thereof.

8. The composition of any one of claims 1 to 7, wherein the first inhibitor compound is present in the composition at a concentration of about 0.01 wt% to about 80 wt%.

9. The composition of any one of claims 1 to 8, wherein the second inhibitor compound is present in the composition at a concentration of about 0.01 wt% to about 50 wt%.

10. The composition of any one of claims 1 to 9, wherein the molar ratio of the first inhibitor compound to the second inhibitor compound is from about 100:1 to about 1:

100.

11. The composition according to any one of claims 1 to 10, wherein the composition further comprises an organic solvent.

12. The composition of any one of claims 1 to 11, wherein the composition further comprises an ethylenically unsaturated monomer selected from the group consisting of vinyl acetate, acrylonitrile, acrylates, methacrylates, 1,3-butadiene, styrene, isoprene, cyclopentadiene, dicyclopentadiene, acrylic acid, methacrylic acid, and any combination thereof.

13. A method for inhibiting monomer polymerization, the method comprising: The composition according to any one of claims 1 to 12 is added to the monomer.

14. The method of claim 13, wherein the monomer is provided in solution.

15. The method of claim 14, wherein the solution further comprises one or more additional components selected from the group consisting of an acid, an organic solvent, and water.

16. The method of any one of claims 13 to 15, wherein the monomer is an ethylenically unsaturated monomer.

17. The method of any one of claims 13 to 16, wherein the composition is added to the monomer such that the concentration of the first inhibitor compound is from about 0.1 ppm to about 10,000 ppm.

18. The method of any one of claims 13 to 16, wherein the composition is added to the monomer such that the concentration of the second inhibitor compound is from about 0.1 ppm to about 10,000 ppm.

19. The method of any one of claims 13 to 18, wherein the monomer is selected from the group consisting of vinyl acetate, acrylonitrile, acrylates, methacrylates, 1,3-butadiene, styrene, divinylbenzene, isoprene, cyclopentadiene, dicyclopentadiene, acrylic acid, methacrylic acid, and any combination thereof.